Comparison
CJC-1295 vs Magnesium L-Threonate
Side-by-side of CJC-1295 and Magnesium L-Threonate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Magnesium L-Threonate
Magnesium l-threonate (Magtein) crosses the blood-brain barrier. Typical dose 1,500-2,000 mg. Sleep and cognitive trial data, side effects.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Magnesium L-Threonate
- •Distinct magnesium salt designed for blood-brain barrier penetration; not a higher-quality systemic magnesium
- •Liu 2010 rodent study: elevated CSF magnesium ~15% and increased hippocampal synaptic density
- •Trial portfolio in humans is small and mostly Magtein-funded; cognitive effects are modest where reported
- •Typical dose 1500 to 2000 mg/day delivers only ~108 to 144 mg of elemental magnesium
- •GI tolerability comparable to other magnesium forms; loose stools in a minority at 2000 mg/day
- •Distinct from magnesium glycinate, which is the conventional sleep/anxiety/repletion form
Side-by-side
| Attribute | CJC-1295 | Magnesium L-Threonate |
|---|---|---|
| Category | peptide | supplement |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | Mg-T, MgT, Magtein, magnesium threonate |
| Half-life (hr) ↗ | 168 | 4 |
| Typical dose (mg) ↗ | 0.1 | 2000 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | 1 to 3 times daily |
| Routes | subcutaneous | oral |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 3 | 2 |
| Molecular weight | 3367.83 | 294.5 |
| Molecular formula | C152H252N44O42 | C8H14MgO10 |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Proposed to deliver magnesium across the blood-brain barrier more effectively than other oral salts via threonate-related transporters, raising CNS magnesium and modulating NMDA receptor function and synaptic plasticity. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | OTC dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement (not scheduled) |
| Pregnancy | Insufficient data; not recommended | Standard magnesium safety; Mg-T-specific data limited |
| CAS | 446262-90-4 | 778571-57-6 |
| PubChem CID | 91971820 | 10691810 |
| Wikidata | Q5012154 | Q27151568 |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Magnesium L-Threonate
Common side effects
- loose stools
- mild GI upset
- headache (rare)
- fatigue (rare)
Contraindications
- severe renal impairment (eGFR below 30)
- hypermagnesemia
- myasthenia gravis (high doses)
- concurrent IV magnesium therapy
Interactions
- tetracyclines and fluoroquinolones: magnesium chelation reduces antibiotic absorption; separate by 2 to 4 hours(moderate)
- bisphosphonates: reduced absorption; separate by 2 hours minimum(moderate)
- muscle relaxants and aminoglycosides: potentiated neuromuscular blockade at high doses(moderate)
- antihypertensives: additive blood pressure reduction at high doses(minor)
Which Should You Take?
Magnesium L-Threonate comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is focus or working memory, pick Magnesium L-Threonate.
- → If your priority is sleep onset or sleep quality, pick Magnesium L-Threonate.
Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium L-Threonate is the more accessible choice.
Default choice: Magnesium L-Threonate. Lower friction to source, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Magnesium L-Threonate?
CJC-1295 and Magnesium L-Threonate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Magnesium L-Threonate?
CJC-1295 half-life is 168 hours; Magnesium L-Threonate half-life is 4 hours.
Can you stack CJC-1295 with Magnesium L-Threonate?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper